Amphotericin B lipid complex: Treatment of invasive fungal infections in patients refractory to or intolerant of amphotericin B deoxycholate

Therapeutics and Clinical Risk Management

Volumn 4, Issue 6, 2008, Pages 1285-1294

  Chandrasekar, P H ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

Amphotericin B lipid complex; Invasive fungal infections

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CORTICOSTEROID; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DIMYRISTOYLPHOSPHATIDYLGLYCEROL; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; POLYENE; POSACONAZOLE; PYRROLE DERIVATIVE; VORICONAZOLE;

ASPERGILLOSIS; BLASTOMYCOSIS; CANDIDEMIA; CENTRAL NERVOUS SYSTEM INFECTION; CHILL; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; CREATININE BLOOD LEVEL; CRYPTOCOCCOSIS; DIALYSIS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FEVER; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FUSARIOSIS; GRAFT VERSUS HOST REACTION; HISTOPLASMOSIS; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; INVASIVE CANDIDIASIS; KIDNEY DISEASE; KIDNEY FUNCTION; LIVER TOXICITY; LUNG DISEASE; MUCORMYCOSIS; MYCOSIS; NAUSEA; NEPHROTOXICITY; NEUTROPHIL COUNT; NONHUMAN; RECOMMENDED DRUG DOSE; REVIEW; SCEDOSPORIOSIS; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; VOMITING;

EID: 61549084407     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/tcrm.s1554     Document Type: Review

References (40)

1. Adedoyin A, Bernardo JF, Swenson CE et al. 1997, Pharmacokinetic profile of Abelcet (amphotericin B lipid complex injection): combined experience from phase I and phase II studies. Antimicrob Agents Chemother, 41:2201-8.
2. Adler-Shohet FC, Arrieta AC, Ross LA et al. 2001. Amphotericin B lipid complex in neonates with invasive candidiasis. Clin Infect Dis, 33:1198.
3. Alexander BD, Wingard JR. 2005. Study of renal safety in amphotericin B lipid complex-treated patients. Clin Infect Dis, 40(Suppl 6):S414-S21.
4. Baddour LM, Perfect JR, Ostrosky-Zeichner L. 2005. Successful use of amphotericin B lipid complex in the treatment of cryptococcosis. Clin Infect Dis, 40 (Suppl 6): S409-S13.
5. Barrett JP, Vardulaki KA, Conlon C, et al. 2003. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther, 25:1295-320.
6. Cannon JP, Garey KW, Danziger LH. 2001. A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations. Pharmacother, 21:1107-14.
7. Chamilos G, Luna M, Lewis RE, et al. 2006. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica, 91:986-9.
8. Chandrasekar PH, Ito JI. 2005. Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients. Clin Infect Dis, 40(Suppl 6):S392-S400.
9. Fleming RV, Kantarjian HM, Husni R, et al. 2001. Comparison of amphotericin B lipid complex (ABLC) vs. AmBisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leukemia Lymphoma, 40:511-20.
10. Gilgado F, Serena C, Cano J, et al. 2006. Antifungal susceptibilities of the species of the Pseudallescheria boydii complex. Antimicrob Agents Chemother, 50:4211-13.
11. Hawkins JL, Baddour LM. 2003. Candida lusitaniae infections in the era of fluconazole availability. Clin Infect Dis, 36:e14-e18.
12. Herbrecht R, Auvrignon A, Andres E, et al. 2001. Efficacy of amphotericin B lipid complex in the treatment of invasive fungal infections in immunosuppressed paediatric patients. Eur J Clin Microbiol Infect Dis, 20:77-82.
13. Herbrecht R, Denning DW, Patterson TF, et al. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med, 347:408-15.
14. Hooshmand-Rad R, Chu A, Gotz V, et al. 2005. Use of amphotericin B lipid complex in elderly patients. J Infect, 50:277-87.
15. Ito JI, Chandrasekar PH, Hooshmand-Rad R. 2005. Effectiveness of amphotericin B lipid complex (ABLC) treatment in allogeneic hematopoietic cell transplant (HCT) recipients with invasive aspergillosis (IA). Bone Marrow Transplant, 36:873-7.
16. Ito JI, Hooshmand-Rad R. 2005. Treatment of Candida infections with amphotericin B lipid complex. Clin Infect Dis, 40(Suppl 6):S384-91.
17. Janoff AS, Perkins WR, Saletan SI, et al. 1993. Amphotericin B lipid complex (ABLC): a molecular rationale for the attenuation of amphotericin B related toxicities. J Liposomes Res, 3:451-71.
18. Johnson PC, Wheat LI, Cloud GA, et al. 2002. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med, 137:105-9.
19. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. 2005. Zygomycosis in a tertiary care cancer center in the era of Aspergillus-active antifungal therapy: a case-controled observational study of 27 recent cases. J Infect Dis, 191:1350-9.
20. Larkin JA, Montero JA. 2003. Efficacy and safety of amphotericin B lipid complex for zygomycosis. Infect Med, 20:201-6.
21. Lewis RE, Liao G, Hou J, et al. 2007. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother, 51:1253-58.
22. Linden P, Williams P and Chan KM. 2000. Efficacy and safety of amphotericin B lipid complex in injection (ABLC) in solid-organ transplant recipients with invasive fungal infections. Clin Transplant, 14:329-39.
23. Martin GS, Mannino DM, Eaton S, et al. 2003. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med, 348:1546-54.
24. Martino R. 2004. Efficacy, safety and cost-effectiveness of amphotericin B lipid complex (ABLC): a review of the literature. Curr Med Res Opin, 20:485-504.
25. Martino R, Cortes M, Subira M, et al. 2005. Efficacy and toxicity of intermediate dose amphotericin B lipid complex as a primary or salvage treatment of fungal infections in patients with hematologic malignancies. Leuk Lymphoma, 46:1429-3 5.
26. Ostrosky-Zeichner L, Pappas PG. 2006. Invasive candidiasis in the intensive care unit. Crit Care Med, 34:857-62.
27. Pappas PG (ed). 2005. Amphotericin B lipid complex in the treatment of invasive fungal infections: results of the Collaborative Exchange of Antifungal Research (CLEAR), an industry-supported patient registry. Clin Infect Dis, 40(Suppl 6):S379-S83.
28. Perfect JR. 2005. Treatment of non-aspergillus molds in immunocompromised patients with amphotericin B lipid complex. Clin Infect Dis, 40(Suppl 6): S401-S408.
29. Perfect JR, Marr KA, Walsh TJ, et al. 2003. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis, 36:1122-31.
30. Roden MM, Zaoutis TE, Buchanan WL, et al. 2005. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis, 41:634-53.
31. Saag MS, Graybill RJ, Larsen RA, et al. 2000. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis, 30:710-18.
32. Safdar A, Ma J, Walsh TJ, et al. 2007. Nephrotoxicity associated with amphotericin B (AmB) lipid complex (ABLC) vs. liposomal amphotericin B (L-AmB). 47th Interscience Conference on Antimicrobial Agents and Chemotherap, Abstract M-1168, pg 442.
33. Sharkey PK, Graybill JR, Johnson ES, et al. 1996. Amphotericiin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis, 22:315-21.
34. Sutton DA, Sanche SE, Revankar SG, et al. 1999. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head to head comparison to voriconazole. J Clin Microbiol, 37:2343-5.
35. van Burik JA, Hare RS, Solomon HF, et al. 2006. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis, 42:e61-e5.
36. Walsh TJ, Hiemenz JW, Seibel NL, et al. 1998. Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases. Clin Infect Dis, 26:1383-96.
37. Wheat LI, Cloud G, Johnson PC, et al. 2001. Clearmce of fungal burden during treatment of disseminated histoplasmosis with liposomal amphotericin B versus itraconazole. Antimicrob Agents Chemother, 45:2354-7.
38. Wiley JM, Seibel NL and Walsh TJ. 2005. Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections. Pediatr Infect Dis J, 24:167-74.
39. Wingard JR. 1997. Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses. Bone Marrow Transplant, 19:343-7.
40. Wingard JR, White MH, Anaissie E, et al. 2000. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis, 31:1155-63.